Forte Biosciences, Inc.
Clinical-stage biopharma developing FB102 for autoimmune diseases like celiac, vitiligo, & alopecia.
FBRX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US8888461022 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 3060 PEGASUS PARK DRIVE, 75247 DALLAS
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and autoimmune-related diseases. The company's lead product candidate is FB102, a proprietary molecule with potentially broad therapeutic applications. Forte is advancing FB102 through its clinical pipeline, with ongoing trials for conditions including a Phase 2 study for celiac disease, as well as studies for vitiligo and alopecia areata.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Forte Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Forte Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Forte Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
